GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
India plays a critical role in Bristol Myers Squibb’s global strategy
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Subscribe To Our Newsletter & Stay Updated